Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates.
Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates.
复制标题
使用 INO-4800 和 INO-4802 的初免加强疫苗接种方案可增强和扩大非人灵长类动物针对 SARS-CoV-2 的免疫反应。
DOI：
10.1016/j.vaccine.2022.03.060
复制
发表时间：
2022-05-09
期刊：
影响因子：
5.5
通讯作者：
Broderick KE
中科院分区：
文献类型：
--
作者：
Walters JN;Schouest B;Patel A;Reuschel EL;Schultheis K;Parzych E;Maricic I;Gary EN;Purwar M;Andrade VM;Doan A;Elwood D;Eblimit Z;Nguyen B;Frase D;Zaidi FI;Kulkarni A;Generotti A;Joseph Kim J;Humeau LM;Ramos SJ;Smith TRF;Weiner DB;Broderick KE
The enhanced transmissibility and immune evasion associated with emerging SARS-CoV-2 variants demands the development of next-generation vaccines capable of inducing superior protection amid a shifting pandemic landscape. Since a portion of the global population harbors some level of immunity from vaccines based on the original Wuhan-Hu-1 SARS-CoV-2 sequence or natural infection, an important question going forward is whether this immunity can be boosted by next-generation vaccines that target emerging variants while simultaneously maintaining long-term protection against existing strains. Here, we evaluated the immunogenicity of INO-4800, our synthetic DNA vaccine candidate for COVID-19 currently in clinical evaluation, and INO-4802, a next-generation DNA vaccine designed to broadly target emerging SARS-CoV-2 variants, as booster vaccines in nonhuman primates. Rhesus macaques primed over one year prior with the first-generation INO-4800 vaccine were boosted with either INO-4800 or INO-4802 in homologous or heterologous prime-boost regimens. Both boosting schedules led to an expansion of T cells and antibody responses which were characterized by improved neutralizing and ACE2 blocking activity across wild-type SARS-CoV-2 as well as multiple variants of concern. These data illustrate the durability of immunity following vaccination with INO-4800 and additionally support the use of either INO-4800 or INO-4802 in prime-boost regimens.
登录
查看更多内容
影响因子：
5.5
作者：
Maslow JN
通讯作者：
Maslow JN
影响因子：
56.9
作者：
Kissler, Stephen M.;Tedijanto, Christine;Lipsitch, Marc
通讯作者：
Lipsitch, Marc
DOI：
10.1016/s0140-6736(21)01694-9
发表时间：
2021-09-04
期刊：
Lancet (London, England)
影响因子：
--
作者：
Liu X;Shaw RH;Stuart ASV;Greenland M;Aley PK;Andrews NJ;Cameron JC;Charlton S;Clutterbuck EA;Collins AM;Dinesh T;England A;Faust SN;Ferreira DM;Finn A;Green CA;Hallis B;Heath PT;Hill H;Lambe T;Lazarus R;Libri V;Long F;Mujadidi YF;Plested EL;Provstgaard-Morys S;Ramasamy MN;Ramsay M;Read RC;Robinson H;Singh N;Turner DPJ;Turner PJ;Walker LL;White R;Nguyen-Van-Tam JS;Snape MD;Com-COV Study Group
通讯作者：
Com-COV Study Group
DOI：
10.1056/nejmoa2102214
发表时间：
2021-05-20
期刊：
The New England journal of medicine
影响因子：
--
作者：
Madhi SA;Baillie V;Cutland CL;Voysey M;Koen AL;Fairlie L;Padayachee SD;Dheda K;Barnabas SL;Bhorat QE;Briner C;Kwatra G;Ahmed K;Aley P;Bhikha S;Bhiman JN;Bhorat AE;du Plessis J;Esmail A;Groenewald M;Horne E;Hwa SH;Jose A;Lambe T;Laubscher M;Malahleha M;Masenya M;Masilela M;McKenzie S;Molapo K;Moultrie A;Oelofse S;Patel F;Pillay S;Rhead S;Rodel H;Rossouw L;Taoushanis C;Tegally H;Thombrayil A;van Eck S;Wibmer CK;Durham NM;Kelly EJ;Villafana TL;Gilbert S;Pollard AJ;de Oliveira T;Moore PL;Sigal A;Izu A;NGS-SA Group;Wits-VIDA COVID Group
通讯作者：
Wits-VIDA COVID Group
影响因子：
82.9
作者：
Juno, Jennifer A.;Tan, Hyon-Xhi;Wheatley, Adam K.
通讯作者：
Wheatley, Adam K.